Nav: Home

Long-term treatment of decompensated cirrhosis with human albumin improves survival

April 22, 2017

April 22, 2017, Amsterdam, The Netherlands: Results from the ANSWER study presented today showed that long-term administration of human albumin improves the survival rate of patients with decompensated cirrhosis (the symptomatic stage of chronic liver disease). The study, presented at The International Liver Congress™ 2017 in Amsterdam, The Netherlands, demonstrated that treatment with human albumin also improved the management of ascites (accumulation of fluid in the abdominal cavity) and quality of life, and reduced the incidence of severe complications of the disease and the need for hospitalisation.

Decompensated cirrhosis occurs after severe fibrosis deposition (scarring) and a mass reduction in liver cells, as a consequence of long-lasting liver injury, and when the circulation and function of the organ are compromised (portal hypertension and liver insufficiency).1 Following decompensation, cirrhosis becomes a systemic disease, with multi-organ dysfunction and, ultimately, failure. As a result, patients with decompensated cirrhosis have a poor prognosis with the one-year probability of mortality being 20%.2 The only curative therapy currently available is liver transplantation.3 Therapies which improve survival in decompensated cirrhosis are an important unmet need in hepatology.

Human albumin is a relatively small protein synthesised by liver cells that plays a vital role in regulating fluid distribution in the body. Moreover, the albumin molecule is a potent scavenger of reactive oxygen and nitrogen species, and binds and transports exogenous and endogenous toxic substances.4 Due to the reduced function of the liver, patients with cirrhosis often have low albumin levels in the blood.4 Human albumin has been used for many years to treat some of the most severe complications of cirrhosis in the acute setting.5

"There has been a lack of scientific evidence proving that long-term human albumin can treat cirrhosis with ascites," said Prof Mauro Bernardi, University of Bologna, Italy, and author of the study. "The ANSWER study has now clarified this issue, showing that human albumin extends survival and helps better manage ascites, as well as reducing the incidence of severe complications of this very serious disease."

The ANSWER study was a randomised, controlled trial of 440 patients with cirrhosis and uncomplicated ascites that compared standard diuretic therapy with standard diuretic therapy plus human albumin (40 g intravenously twice weekly in the first two weeks and then once weekly). The primary endpoint was overall survival and patients were followed for up to 18 months.

The rate of survival was significantly higher in patients receiving human albumin plus to standard therapy, compared with those receiving standard therapy only. Treatment with human albumin reduced the risk of death by 38%. Statistically significant benefits of administering human albumin rather than standard therapy alone were demonstrated for the management of ascites, complications of cirrhosis, quality of life and hospital admissions.

"The reduction in mortality observed in the albumin-treated arm of this randomised controlled study is a novel and important piece of information. Based on this data, weekly administration of albumin should be considered in patients with cirrhosis and ascites to prevent life-threatening complications," said Prof Annalisa Berzigotti, University Clinic for Visceral Surgery and Medicine, University of Berne, Switzerland, and EASL Governing Board Member.
About The International Liver Congress™

This annual congress is the biggest event in the EASL calendar, attracting scientific and medical experts from around the world to learn about the latest in liver research. Attending specialists present, share, debate and conclude on the latest science and research in hepatology, working to enhance the treatment and management of liver disease in clinical practice. This year, the congress is expected to attract approximately 10,000 delegates from all corners of the globe. The International Liver Congress™ 2017 will take place from April 19 - 23, at the RAI Amsterdam, Amsterdam, The Netherlands.

About The European Association for the Study of the Liver (EASL)

Since its foundation in 1966, this not-for-profit organisation has grown to over 4,000 members from all over the world, including many of the leading hepatologists in Europe and beyond. EASL is the leading liver association in Europe, having evolved into a major European Association with international influence, with an impressive track record in promoting research in liver disease, supporting wider education and promoting changes in European liver policy.


For more information, please contact the ILC Press Office at:Onsite location reference

Session title: Late breaker session
Time, date and location of session: 16:00 - 18:00, Saturday 22 April, Hall 5
Presenter: Mauro Bernardi, Italy
Abstract: Long-term albumin administration improves survival in patients with decompensated cirrhosis: final results of the "ANSWER" study (LBO-08), 17:45 - 18:00

Author disclosures

Consultant: CLS Behring GmbH, Baxter Healthcare SA
Speaker: CLS Behring GmbH, PPTA Europe, Baxter Healthcare SA, Grifols SA, Gilead Sciences, AbbVie Italy.


1 British Liver Trust. Cirrhosis of the liver. Available from: Last accessed: April 2017.
2 Zipprich A, Garcia-Tsao G, Rogowski S, et al. Prognostic indicators of survival in patients with compensated and decompensated cirrhosis. Liver Int. 2012 Oct;32(9):1407-1414.
3 European Association for the Study of Liver. The burden of liver disease in Europe. A review of epidemiological data. Available from: Last accessed: April 2017.
4 Bernardi M et al. Role of human albumin in the management of complications of liver cirrhosis. J Clin Exp Hepatol. 2014;4(4):302-11.
5 Arroyo V, Garcia-Martinez R, Salvatella X. Human serum albumin, systemic inflammation, and cirrhosis. J Hepatol. 2014;61(2):396-40.

European Association for the Study of the Liver

Related Cirrhosis Articles:

Abnormal gut bugs tied to worse cognitive performance in vets with PTSD and cirrhosis
A study involving military veterans with PTSD and cirrhosis of the liver points to an abnormal mix of bacteria in the intestines as a possible driver of poor cognitive performance -- and as a potential target for therapy.
Movement toward a poop test for liver cirrhosis
In a study of people with nonalcoholic fatty liver disease and their twins and other close relatives, UC San Diego researchers were able to diagnose liver cirrhosis simply by analyzing a person's stool microbes.
Gum disease treatment may improve symptoms in cirrhosis patients
Routine oral care to treat gum disease (periodontitis) may play a role in reducing inflammation and toxins in the blood (endotoxemia) and improving cognitive function in people with liver cirrhosis.
Alcohol-related cirrhosis deaths skyrocket in young adults
Liver disease deaths jumped by 65 percent in the United States, from 1999-2016, disproportionately affecting adults ages 25-34.
Researchers find a promising new approach for treating liver cirrhosis
In a study in The American Journal of Pathology, investigators report that treatment with aleglitazar, a dual peroxisome proliferator-activated receptor-alpha/gamma (PPARα/γ) agonist, reduced inflammation, vasoconstriction, angiogenesis, mucosal disruption, and tumor necrosis factor (TNF)-α overproduction in cirrhotic rats with PH.
Study: Alcohol-related cirrhosis patients are sicker, costlier and often female
A new review by Michigan Medicine finds that women drinkers are disproportionately affected in alcohol-related cirrhosis cases.
A third of bacterial infections in patients with cirrhosis across the world are multi-drug resistant
An international study reports a high prevalence of multi-drug-resistant bacteria in hospitalized patients with cirrhosis and significant regional differences in risk.
Gut microbes could help better predict risk of hospitalization for patients with cirrhosis
The gut microbiome -- a collection of bacteria and other microbes in the gut -- could be a highly accurate predictor of hospitalizations for patients with cirrhosis, according to a recently published study led by a researcher at Virginia Commonwealth University.
A South American amphibian could potentially hold the key in curing cirrhosis
The unique liver function of a South American amphibian, Siphonops annulatus, could pave the way to finding a cure to the devastating liver condition cirrhosis, a new study published in the prestigious Journal of Anatomy reports.
Cholesterol-lowering drugs may help patients with cirrhosis
Statins used for the treatment of high cholesterol may have other beneficial effects, but there has been reluctance to prescribe them to patients with liver disease because of concerns that they may cause abnormal liver enzyme levels in the blood.
More Cirrhosis News and Cirrhosis Current Events

Top Science Podcasts

We have hand picked the top science podcasts of 2019.
Now Playing: TED Radio Hour

In & Out Of Love
We think of love as a mysterious, unknowable force. Something that happens to us. But what if we could control it? This hour, TED speakers on whether we can decide to fall in — and out of — love. Guests include writer Mandy Len Catron, biological anthropologist Helen Fisher, musician Dessa, One Love CEO Katie Hood, and psychologist Guy Winch.
Now Playing: Science for the People

#543 Give a Nerd a Gift
Yup, you guessed it... it's Science for the People's annual holiday episode that helps you figure out what sciency books and gifts to get that special nerd on your list. Or maybe you're looking to build up your reading list for the holiday break and a geeky Christmas sweater to wear to an upcoming party. Returning are pop-science power-readers John Dupuis and Joanne Manaster to dish on the best science books they read this past year. And Rachelle Saunders and Bethany Brookshire squee in delight over some truly delightful science-themed non-book objects for those whose bookshelves are already full. Since...
Now Playing: Radiolab

An Announcement from Radiolab